Target intelligence / Profile preview

Ribosomal protein L22 pseudogene 14 (RPL22P14)

Target: RPL22P14
Molecular classification: Other (Processed pseudogene)

Overview

Ribosomal protein L22 pseudogene 14 (RPL22P14) is a human processed pseudogene related to the ribosomal protein L22 gene family. Like other pseudogenes, RPL22P14 does not encode a functional protein and is not transcribed into a protein product involved in cellular processes. Pseudogenes such as RPL22P14 arise from duplication or retrotransposition events and are typically non-functional genetic elements; some can have regulatory roles, but there is currently no evidence that RPL22P14 plays a significant regulatory or biological role. It is not considered a therapeutic target, biomarker, or associated with disease phenotypes, and there are no known drugs or safety concerns linked to this pseudogene[2][3][9].

Other names: RPL22_8_723[2][9]

Beyond the preview

Go deeper on Ribosomal protein L22 pseudogene 14 (RPL22P14).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribosomal protein L22 pseudogene 14 (RPL22P14).

Explore the full profile